News | September 22, 2014

New Study Examines Effect of Percutaneous PFO Closure on Migraine Headaches

Results of PRIMA trial reported at TCT 2014

September 22, 2014 — According to a new study, while it is common for patients who have migraine to have a patent foramen ovale, a procedure to repair this heart defect does not significantly reduce total migraine days compared to medical therapy. The findings were reported at the 26th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C.

Patent foramen ovale (PFO) is a defect between the atrial chambers of the heart. Patients who have migraine frequently have a PFO, and observational studies of PFO closure have shown a reduction in the frequency and severity of migraine attacks.

The PRIMA trial evaluated whether percutaneous PFO closure is effective in reducing migraine headaches in patients who have migraine, compared to medical treatment. The primary endpoint was reduction in migraine days one year after randomization. Secondary endpoints included reduction in migraine with aura days, reduction in migraine with aura attacks and freedom from migraines.

The multicenter trial with blinded endpoints randomized 107 patients with refractory migraine with aura and PFO to either receive either PFO closure (n=53) or medical management (n=54). A total of 83 patients completed the 12-month follow-up.

The mean reduction in migraine days was -2.9 days in the device closure group and -1.7 days in the medical management group (p=0.17). Respective mean reduction in migraine with aura days was -2.4 days versus -0.6 days, respectively (p=0.01). Monthly mean reduction of migraine with aura attacks were -2.0 in the device closure group compared to -0.5 in the medical management group (p<0.01). A reduction of migraine days greater than or equal to 50 percent was achieved in 37.5 percent of the device closure group compared to 14.6 percent in the medical management group (p=0.02).

“In patients with refractory migraine with aura and a PFO, percutaneous PFO closure did not significantly reduce the overall monthly migraine days,” said investigator David Hildick-Smith, M.D. from the Sussex Cardiac Center in Brighton, England. “However the procedure did significantly reduce migraine with aura days and attacks, and also improved responder rates.”

The PRIMA trial was funded by St. Jude Medical. Hildick-Smith reported grant support from St. Jude Medical.

For more information: www.crf.org, www.tctconference.com

Related Content

Novel Index Accurately Predicts PCI Success Post-Procedure Compared to Established Measurement Metrics
News | Cath Lab | June 19, 2019
Results from a comprehensive analysis demonstrate the effectiveness of measuring a non-hyperemic pressure ratio (NHPR...
Philips Healthcare, Volcano IVUS showing an implanted stent. IVUS might offer an alternative to contrast angiography in patients with acute kidney disease (AKD).
News | Cath Lab | June 14, 2019
June 14, 2019 – A late-breaking study examined the effects of intravascular ultrasound (IVUS) guided drug-eluting ste
Videos | Cath Lab | May 20, 2019
This is a walk through of the primary structural heart hybrid cath lab at...
Mobility May Predict Elderly Heart Attack Survivors' Repeat Hospital Stays
News | Cath Lab | April 23, 2019
Determining which elderly heart attack patients take longer to stand from a seated position and walk across a room may...
FDA Releases New Guidance on Medical Devices Containing Nitinol
News | Cath Lab | April 18, 2019
April 18, 2019 — The U.S.
Angiography shows a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL lithoplasty.

Figure 2: Angiography demonstrates a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification (double-headed arrow) in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL (inset; note the cavitation bubbles generated by IVL [black arrows]). (D) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-IVL and coregistered to the OCT lens (white arrow in C) demonstrate multiple calcium fractures and large acute luminal gain. (E) Angiography demonstrates complete stent expansion with the semicompliant stent balloon (inset) without the need for high-pressure noncompliant balloon inflation. (F) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-stenting and coregistered to the OCT lens (arrow in E) demonstrate further fracture displacement (arrow), with additional increase in the acute area gain (5.17 mm2), resulting in full stent expansion and minimal malapposition.

Feature | Cath Lab | April 15, 2019 | Dean Kereiakes, M.D., FACC, FSCAI, and Jonathan Hill, M.D., DISRUPT CAD III Co-Principal Investigators
Over the last 40 years, despite multiple advancements in percutaneous coronary interventions, calcified lesions remai
BIOTRONIK’s PK Papyrus covered coronary stent. The stent ius used in emergency coronary artery dissections to repair the vessel wall.
Technology | Cath Lab | April 15, 2019
April 15, 2019 — Biotronik began its U.S.
Providing Follow-Up Care After Heart Attack Helps Reduce Readmissions, Deaths
News | Cath Lab | April 09, 2019
A program designed to help heart attack patients with the transition from hospital to outpatient care can reduce...
TherOx Receives FDA Approval for SuperSaturated Oxygen Therapy
Technology | Cath Lab | April 08, 2019
TherOx Inc. announced that the U.S. Food and Drug Administration (FDA) granted premarket approval for its...
Overlay Init